Higher discontinuation rates of GLP-1 receptor agonists in non-diabetic patients

January 8, 2025

Study details: This systematic review and meta-analysis examined real-world studies published from 2021 onwards to assess one-year discontinuation rates of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in individuals with overweight and obesity, with and without T2DM. The analysis included 12 studies comprising 445,897 participants.

Results: Nearly half (48.7%) of patients who begin GLP-1 RAs discontinue the medications within one year (95% confidence interval: 39.8% - 57.5%). A significant negative association was found between the proportion of patients with T2DM and the discontinuation rate, with higher discontinuation rates observed in non-diabetic individuals. The primary reasons for discontinuation included GI side effects, high costs, medication shortages, and perceived lack of benefit.

Clinical impact: These findings highlight the need for targeted strategies to improve persistence with GLP-1 RAs, particularly in non-diabetic patients. Addressing barriers such as side effects and cost and educating patients on the benefits of long-term treatment could enhance adherence and support sustained weight loss and cardiometabolic health benefits.

Source:

Grosicki GJ, et al. (2025, January 2). Diabetes Obes Metab. Glucagon-like peptide-1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes. https://pubmed.ncbi.nlm.nih.gov/39743934/